ReviewDrugs1997
Antifungal agents in the 1990s. Current status and future developments.
Review in Drugs, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Annals of hematology · 2003Guideline
- Antifungal Drug Efficacy Profiles Against VaginalJournal of clinical medicine · 2025Article
- Eugenol: A novel therapeutic agent for the inhibition ofFrontiers in pharmacology · 2022Review
- Evaluation of Antifungal Effect of Silver Nanoparticles AgainstIranian journal of biotechnology · 2015Article
- Antifungal Properties of Chenopodium ambrosioides Essential Oil Against Candida Species.Pharmaceuticals (Basel, Switzerland) · 2010Article
- In vitro activity of eugenol against Candida albicans biofilms.Mycopathologia · 2007Article
- In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.Antimicrobial agents and chemotherapy · 2003Article
- Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.Antimicrobial agents and chemotherapy · 2002Article
- Experimental oral candidiasis in animal models.Clinical microbiology reviews · 2001Review
- Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest.Journal of clinical microbiology · 2001Article
- Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.Clinical pharmacokinetics · 2000Review
- A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.Journal of bacteriology · 1999Article
- Current and emerging azole antifungal agents.Clinical microbiology reviews · 1999Review
- Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.Journal of clinical microbiology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Significant advances in antifungal therapy have occurred in the last decade. Most of these advances have been tied to the introduction of the triazoles, itraconazole and fluconazole. Itraconazole has proved efficacious for the treatment of subacute to chronic infections with the endemic mycoses and other opportunistic filamentous fungi, including Aspergillus spp. Fluconazole is now routinely used for mucocutaneous and systemic candidiasis, and its use for coccidioidal meningitis has obviated the need for intrathecal amphotericin B in most patients. Large, well controlled trials in AIDS patients with cryptococcal meningitis have shown the benefit of induction therapy with amphotericin B and flucytosine, followed by consolidation and life-long maintenance therapy with fluconazole. Concomitant with the increased use of these well tolerated, effective oral triazole agents has come the emergence of drug resistance in AIDS patients and shifts in the species of yeasts causing infection in hospitalised patients. Amphotericin B remains the drug of choice for many fungal infections, especially those that are life-threatening. Lipid-containing formulations of amphotericin B have recently been approved: these preparations significantly reduce the risk of amphotericin B-induced nephrotoxicity. Several new fungicidal agents are currently in early trials. With the increasing number of available antifungal drugs, future studies will help define the appropriate niche for each and the possible benefit of therapy with combinations of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.